Polymorphisms at - 174 and in the 3' flanking region of interleukin-6 (IL-6) gene in patients with myasthenia gravis.
We examined the bi-allelic polymorphism at - 174 in the promoter region and the polymorphism in the 3' flanking AT rich region of the interleukin-6 (IL-6) gene in Swedish patients with myasthenia gravis (MG) and ethnically matched healthy individuals. There was no association between the polymorphisms and the disease. There was no relation of the polymorphisms to the clinical variables, the thymic histopathologies, the level of serum acetylcholine receptor antibodies or the concentrations of IgG and its subclasses. Our data yield no evidence for the IL-6 gene contributing to the disease susceptibility.
Huang
D
D
The Immunological Research Unit, Center for Molecular Medicine (CMM) L8:03, Karolinska Institutet, Stockholm, Sweden. huang.de.ren@cmm.ki.se
Zheng
C
C
Giscombe
R
R
Matell
G
G
Pirskanen
R
R
Lefvert
A K
AK
D020856:AT Rich Sequence; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000145:classification; D015850:Interleukin-6 / Q000235:genetics*; D008297:Male; D009157:Myasthenia Gravis / Q000235:genetics* / Q000276:immunology; D011110:Polymorphism, Genetic
D007074:Immunoglobulin G; D015850:Interleukin-6